Teva Pharmaceutical Industries Limited (TEVA) Short Interest Up 5.7% in September

Teva Pharmaceutical Industries Limited (NYSE:TEVA) was the target of a large increase in short interest during the month of September. As of September 29th, there was short interest totalling 44,659,599 shares, an increase of 5.7% from the September 15th total of 42,266,528 shares. Based on an average trading volume of 16,022,193 shares, the short-interest ratio is currently 2.8 days. Currently, 4.4% of the company’s stock are short sold.

A number of large investors have recently modified their holdings of the stock. Capital Research Global Investors boosted its holdings in shares of Teva Pharmaceutical Industries Limited by 13.8% in the 2nd quarter. Capital Research Global Investors now owns 76,325,059 shares of the company’s stock valued at $2,535,518,000 after purchasing an additional 9,260,426 shares in the last quarter. Franklin Resources Inc. boosted its holdings in shares of Teva Pharmaceutical Industries Limited by 11.1% in the 2nd quarter. Franklin Resources Inc. now owns 66,796,897 shares of the company’s stock valued at $2,218,958,000 after purchasing an additional 6,685,844 shares in the last quarter. FMR LLC boosted its holdings in shares of Teva Pharmaceutical Industries Limited by 16.7% in the 2nd quarter. FMR LLC now owns 42,844,979 shares of the company’s stock valued at $1,423,310,000 after purchasing an additional 6,115,853 shares in the last quarter. Capital World Investors boosted its holdings in shares of Teva Pharmaceutical Industries Limited by 41.9% in the 2nd quarter. Capital World Investors now owns 11,068,200 shares of the company’s stock valued at $367,686,000 after purchasing an additional 3,268,200 shares in the last quarter. Finally, Alliancebernstein L.P. boosted its holdings in shares of Teva Pharmaceutical Industries Limited by 32.3% in the 2nd quarter. Alliancebernstein L.P. now owns 11,399,400 shares of the company’s stock valued at $378,688,000 after purchasing an additional 2,782,257 shares in the last quarter. 56.76% of the stock is currently owned by institutional investors and hedge funds.

A number of research analysts have recently commented on the company. Vetr lowered Teva Pharmaceutical Industries Limited from a “hold” rating to a “sell” rating and set a $31.05 price objective on the stock. in a report on Thursday, June 22nd. Cantor Fitzgerald set a $31.00 price objective on Teva Pharmaceutical Industries Limited and gave the company a “hold” rating in a report on Thursday, June 22nd. BidaskClub lowered Teva Pharmaceutical Industries Limited from a “sell” rating to a “strong sell” rating in a report on Wednesday, August 16th. Citigroup Inc. lowered Teva Pharmaceutical Industries Limited from a “buy” rating to a “neutral” rating and lowered their price objective for the company from $32.00 to $19.00 in a report on Wednesday, August 16th. Finally, Maxim Group reissued a “hold” rating and set a $35.00 price objective on shares of Teva Pharmaceutical Industries Limited in a report on Thursday, July 13th. Five analysts have rated the stock with a sell rating, eighteen have issued a hold rating, six have given a buy rating and one has given a strong buy rating to the company’s stock. Teva Pharmaceutical Industries Limited presently has a consensus rating of “Hold” and a consensus target price of $27.63.

Teva Pharmaceutical Industries Limited (NYSE:TEVA) opened at 14.93 on Friday. Teva Pharmaceutical Industries Limited has a 52-week low of $14.30 and a 52-week high of $44.42. The company’s market cap is $15.17 billion. The company’s 50 day moving average price is $16.59 and its 200 day moving average price is $25.64.

Teva Pharmaceutical Industries Limited (NYSE:TEVA) last issued its quarterly earnings results on Thursday, August 3rd. The company reported $0.99 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $1.06 by ($0.07). The company had revenue of $5.69 billion for the quarter, compared to analyst estimates of $5.72 billion. Teva Pharmaceutical Industries Limited had a positive return on equity of 15.96% and a negative net margin of 25.18%. The company’s quarterly revenue was up 12.9% compared to the same quarter last year. During the same period in the prior year, the company earned $1.25 EPS. Equities research analysts anticipate that Teva Pharmaceutical Industries Limited will post $4.24 EPS for the current fiscal year.

WARNING: “Teva Pharmaceutical Industries Limited (TEVA) Short Interest Up 5.7% in September” was reported by Sports Perspectives and is the property of of Sports Perspectives. If you are accessing this piece on another site, it was stolen and republished in violation of United States and international copyright law. The legal version of this piece can be accessed at https://sportsperspectives.com/2017/10/20/teva-pharmaceutical-industries-limited-teva-short-interest-up-5-7-in-september.html.

About Teva Pharmaceutical Industries Limited

Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.

Receive News & Ratings for Teva Pharmaceutical Industries Limited Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries Limited and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply